분야
pdfJeongho Park
AyseTekin
Jihoon Jeong
Background (https://samsungbiologics.com/upload/prmaterials/2019626114733104.png)
Topics to Review
About Samsung Biologics
Financial Performance
Opportunities & Threats
Elevation Plan for Corporate Value
Forward-Looking Statement
About Samsung Biologics
Drug Substance
Business Model : CDMO
CDO
Business
CMO
Business
Contract Development &
Manufacturing
Organization(CDMO)
Product
(Cell Line)
Process
Analytical
Method
Drug
Substance
Drug
Product
Similar with OEM or Foundry
business
Customer Request
Customer needs
production capacity
Customer needs know-
how and technology Tech
Transfer
(Antibody)
(mRNA)
Drug Product
CustomerShipping
Ownership Structure : Samsung Corporation
Samsung
Electronics(32%)
Common
Stockholders
(25%) Samsung
C&T(43%)
In the stock market, only 25% of all stocks are
being traded. Stock is under control of Samsung
Corporation.
50%+1
Benefit for Stock Price Control
50%-1
Listed in KOSPI US company
According to local regulation in Incheon
city, Samsung Biologics and Biogen
invested and established joint venture
company
CDMO
R&D + Clinical Trial
